Changes in lifestyle, biological risk factors and total homocysteine in relation to MTHFR C677T genotype: A 5-year follow-up study

European Journal of Clinical Nutrition

Volumn 63, Issue 10, 2009, Pages 1233-1240

  Husemoen, L L N ^a   Linneberg, A ^a   Fenger, M ^b   Thuesen, B H ^a   Jorgensen T ^a  

^a Research Centre for Prevention and Health   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CHOLESTEROL; CYSTEINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THREONINE; TRIACYLGLYCEROL;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIETARY INTAKE; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; MALE; PHYSICAL ACTIVITY; RISK FACTOR; SMOKING HABIT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; ALCOHOL DRINKING; BEER; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; COFFEE; CROSS-SECTIONAL STUDIES; DENMARK; FEMALE; FOLLOW-UP STUDIES; FOOD HABITS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOCYSTEINE; HUMANS; LIFE STYLE; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; RISK FACTORS; SMOKING; TEA; WAIST CIRCUMFERENCE;

EID: 70350026168     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2009.59     Document Type: Article

References (47)

1. Aadahl M, von Huth Smith L, Pisinger C, Toft U, Glumer C, Borch-Johnsen K et al. (2009). Five-year change in physical activity is associated with changes in cardiovascular disease risk factors. The inter99 study. Prev Med 48, 326-331.
2. Beulens JW, Sierksma A, Schaafsma G, Kok FJ, Struys EA, Jakobs C et al. (2005). Kinetics of homocysteine metabolism after moderate alcohol consumption. Alcohol Clin Exp Res 29, 739-745.
3. Bleich S, Bleich K, Kropp S, Bittermann HJ, Degner D, Sperling W et al. (2001). Moderate alcohol consumption in social drinkers raises plasma homocysteine levels: A contradiction to the 'French Paradox'? Alcohol Alcohol 36, 189-192.
4. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T et al. (2006). Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354, 1578-1588.
5. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG (1995). A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274 1049-1057.
6. Brown KS, Kluijtmans LA, Young IS, Murray L, McMaster D, Woodside JV et al. (2004). The 5,10-methylenetetrahydrofolate reductase C677T polymorphism interacts with smoking to increase homocysteine. Atherosclerosis 174, 315-322.
7. Clarke R, Lewington S, Donald A, Johnston C, Refsum H, Stratton I et al. (2001). Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies. J Cardiovasc Risk 8, 363-369.
8. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M et al. (1999). Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 150, 341-353.
9. de Bree A, Verschuren WM, Blom HJ (2001a). Biological cardiovascular risk factors and plasma homocysteine levels in the general Dutch population. Atherosclerosis 154, 513-514.
10. de Bree A, Verschuren WM, Blom HJ, Kromhout D (2001b). Lifestyle factors and plasma homocysteine concentrations in a general population sample. Am J Epidemiol 154, 150-154.
11. Dedoussis GV, Panagiotakos DB, Chrysohoou C, Pitsavos C, Zampelas A, Choumerianou D et al. (2004). Effect of interaction between adherence to a Mediterranean diet and the methylenetetrahydrofolate reductase 677C →T mutation on homocysteine concentrations in healthy adults: The ATTICA Study. Am J Clin Nutr 80, 849-854.
12. Duthie SJ, Whalley LJ, Collins AR, Leaper S, Berger K, Deary IJ (2002). Homocysteine, B vitamin status, and cognitive function in the elderly. Am J Clin Nutr 75, 908-913.
13. El Khairy L, Ueland PM, Nygard O, Refsum H, Vollset SE (1999). Lifestyle and cardiovascular disease risk factors as determinants of total cysteine in plasma: The Hordaland Homocysteine Study. Am J Clin Nutr 70, 1016-1024.
14. Elshorbagy AK, Nurk E, Gjesdal CG, Tell GS, Ueland PM, Nygard O et al. (2008). Homocysteine, cysteine, and body composition in the Hordaland Homocysteine Study: Does cysteine link amino acid and lipid metabolism? Am J Clin Nutr 88, 738-746.
15. Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB (2002). Homocyst(e)ine and cardiovascular disease: A systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol 31, 59-70.
16. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al. (1995). A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 10, 111-113.
17. Homocysteine Lowering Trialists' Collaboration (1998). Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ 316, 894-898.
18. Husemoen LL, Thomsen TF, Fenger M, Jorgensen HL, Jorgensen T (2003). Contribution of thermolabile methylenetetrahydrofolate reductase variant to total plasma homocysteine levels in healthy men and women. Inter99 (2). Genet Epidemiol 24, 322-330.
19. Husemoen LL, Thomsen TF, Fenger M, Jorgensen T (2004). Effect of lifestyle factors on plasma total homocysteine concentrations in relation to MTHFR(C677T) genotype. Inter99 (7). Eur J Clin Nutr 58, 1142-1150.
20. Husemoen LL, Thomsen TF, Fenger M, Jorgensen T (2006). Changes in lifestyle and total homocysteine in relation to MTHFR(C677T) genotype: the Inter99 study. Eur J Clin Nutr 60, 614-622.
21. Hustad S, Ueland PM, Vollset SE, Zhang Y, Bjorke-Monsen AL, Schneede J (2000). Riboflavin as a determinant of plasma total homocysteine: Effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin Chem 46, 1065-1071.
22. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH et al. (1996). Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93, 7-9.
23. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J (2001). Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 73, 613-621.
24. Jacques PF, Kalmbach R, Bagley PJ, Russo GT, Rogers G, Wilson PW et al. (2002). The relationship between riboflavin and plasma total homocysteine in the Framingham Offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. J Nutr 132, 283-288.
25. Jorgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C (2003). A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: Baseline results Inter99. Eur J Cardiovasc Prev Rehabil 10, 377-386.
26. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M et al. (2006). Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354, 1567-1577.
27. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE et al. (2004). Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 350, 2042-2049.
28. Meleady R, Ueland PM, Blom H, Whitehead AS, Refsum H, Daly LE et al. (2003). Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: The European Concerted Action Project. Am J Clin Nutr 77, 63-70.
29. Nurk E, Tell GS, Vollset SE, Nygard O, Refsum H, Nilsen RM et al. (2004). Changes in lifestyle and plasma total homocysteine: The Hordaland Homocysteine Study. Am J Clin Nutr 79, 812-819.
30. Nygard O, Refsum H, Ueland PM, Stensvold I, Nordrehaug JE, Kvale G et al. (1997). Coffee consumption and plasma total homocysteine: The Hordaland Homocysteine Study. Am J Clin Nutr 65, 136-143.
31. Nygard O, Refsum H, Ueland PM, Vollset SE (1998). Major lifestyle determinants of plasma total homocysteine distribution: The Hordaland Homocysteine Study. Am J Clin Nutr 67, 263-270.
32. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE et al. (1995). Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 274, 1526-1533.
33. Panagiotakos DB, Pitsavos C, Zeimbekis A, Chrysohoou C, Stefanadis C (2005). The association between lifestyle-related factors and plasma homocysteine levels in healthy individuals from the 'ATTICA' Study. Int J Cardiol 98, 471-477.
34. Rasmussen LB, Ovesen L, Bulow I, Knudsen N, Laurberg P, Perrild H (2000). Folate intake, lifestyle factors, and homocysteine concentrations in younger and older women. Am J Clin Nutr 72 1156-1163.
35. Saw SM, Yuan JM, Ong CN, Arakawa K, Lee HP, Coetzee GA et al. (2001). Genetic, dietary, and other lifestyle determinants of plasma homocysteine concentrations in middle-aged and older Chinese men and women in Singapore. Am J Clin Nutr 73, 232-239.
36. Schmölker L, Fagerstrom K (2000). Gram tobacco 2000. Personal communication.
37. Stein JH, Bushara M, Bushara K, McBride PE, Jorenby DE, Fiore MC (2002). Smoking cessation, but not smoking reduction, reduces plasma homocysteine levels. Clin Cardiol 25, 23-26.
38. Strandhagen E, Zetterberg H, Aires N, Palmer M, Rymo L, Blennow K et al. (2004). The methylenetetrahydrofolate reductase C677T polymorphism is a major determinant of coffee-induced increase of plasma homocysteine: A randomized placebo controlled study. Int J Mol Med 13, 811-815.
39. Thomsen TF, Davidsen M, Ibsen H, Jorgensen T, Jensen G, Borch-Johnsen K (2001). A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials; PRECARD and the Copenhagen Risk Score. J Cardiovasc Risk 8, 291-297.
40. Toft U, Kristoffersen LH, Lau C, Borch-Johnsen K, Jorgensen T (2007). The Dietary Quality Score: Validation and association with cardiovascular risk factors: The Inter99 study. Eur J Clin Nutr 61, 270-278.
41. Tonstad S, Urdal P (2002). Does short-term smoking cessation reduce plasma total homocysteine concentrations? Scand J Clin Lab Invest 62, 279-284.
42. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ et al. (2004). Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291, 565-575.
43. van der Gaag MS, Ubbink JB, Sillanaukee P, Nikkari S, Hendriks HF (2000). Effect of consumption of red wine, spirits, and beer on serum homocysteine. Lancet 355, 1522.
44. Vickers AJ, Altman DG (2001). Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ 323, 1123-1124.
45. Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK et al. (2000). Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: The Hordaland Homocysteine study. Am J Clin Nutr 71, 962-968.
46. von Huth SL, Borch-Johnsen K, Jorgensen T (2007). Commuting physical activity is favourably associated with biological risk factors for cardiovascular disease. Eur J Epidemiol 22, 771-779.
47. Wright M, Francis K, Cornwell P (1998). Effect of acute exercise on plasma homocysteine. J Sports Med Phys Fitness 38, 262-265.